• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

    6/1/22 2:30:00 AM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email

    Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds

    Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed.

    The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). Having previously been approved for the Swiss market, Healiva's® acquisition of the complete product dossier should enable the rapid market re-launch of EpiDex®.

    The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy that has previously demonstrated clinical efficacy in healing VLUs that are resistant to standard treatments.

    "We created Healiva® to improve the lives of the millions suffering from chronic wounds by delivering innovative, effective new treatments to patients," said Healiva's® Founder and CEO, Priyanka Dutta-Passecker, PhD, MBA. "These remarkable cell therapies will make a pivotal contribution to that mission by addressing crucial needs in early- and late-stage chronic wound care. By adding these pioneering technologies to our growing portfolio of wound treatments, we will be able to continue our rapid growth by progressing to commercialization within four years of founding."

    "With 36 million people worldwide currently suffering from chronic wounds, we urgently need novel solutions for hard-to-treat wounds," said Valerio Maria Ferrari, Bioseutica Group Chairman and Co-Founder of Healiva®. "Following this acquisition, we are looking forward to bringing two such solutions to market, beginning with EpiDex® in Switzerland, pending approval by Swissmedic, followed by Germany and other EMEA countries. Meanwhile, for healiva®002, we will improve the product, scale up the manufacturing process, and continue its clinical development for future commercial success at scale."

    Among the populations that may particularly benefit from these new treatments are:

    • The elderly: 2–3% of whom have venous/arterial leg ulcers.
    • People with diabetes: 25% of whom will suffer from potentially disabling diabetic foot ulcers (DFUs) during their lifetime.

    With both of these populations continuing to grow, the burden of chronic wounds and, therefore, the need for new treatments will only become more acute. Today, the standard treatment for VLUs and DFUs requires multiple procedures which come with lengthy recovery times. In severe chronic cases, surgery is required. Crucially, less than 50% of such wounds will heal following surgery and those that do not heal will continue to worsen, potentially leading to amputation or, in severe cases, mortality. In the absence of similar market offerings, EpiDex® fills an important niche by promoting healing even in the most severe wounds, with a closure rate equivalent to surgical methods, while being both more cost-effective and significantly preferable for patients.

    About Healiva®

    Founded in 2020 by Bioseutica BV and Dr. Priyanka Dutta-Passecker, Healiva® is a patient-centric biotech company delivering life-enhancing precision medicine for patients with chronic and acute wounds. Healiva® creates tailored wound solutions through a multi-pronged approach that combines enzyme technology, medical devices, and cell therapies. Cell therapy describes a process in which viable cells are introduced into the body to produce medicinal effects; cells may be derived from a cell bank (allogeneic cell therapy) or be patient-derived cells converted into the desired cell type or tissue in a lab (autologous cell therapy). Through the acquisition, development and commercialization of these assets, Healiva® enters the billion-dollar wound-care market. To find out more, visit healiva.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005734/en/

    Get the next $SNN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    6/5/2024Neutral → Buy
    UBS
    11/28/2023Underweight → Equal Weight
    Barclays
    11/3/2023Neutral → Overweight
    JP Morgan
    More analyst ratings

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of ‘Life Unlimited' - making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint re

      6/29/25 7:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings 'next-level nailing' to trauma surgeons repairing tibial fractures

      The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-ce

      6/24/25 10:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

      6/23/25 8:00:00 AM ET
      $LAZ
      $SNN
      Investment Managers
      Finance
      Industrial Specialties
      Health Care

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

      3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

      2/12/21 6:00:30 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by Berenberg

      Berenberg downgraded Smith & Nephew from Buy to Hold

      11/6/24 6:23:06 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    SEC Filings

    See more
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      7/1/25 11:55:37 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      6/13/25 11:12:35 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      6/6/25 1:20:14 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

      6/23/25 8:00:00 AM ET
      $LAZ
      $SNN
      Investment Managers
      Finance
      Industrial Specialties
      Health Care
    • Cadence Welcomes Bob White to Board of Directors

      STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

      9/12/24 10:57:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Financials

    Live finance-specific insights

    See more
    • Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

      New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

      3/3/25 8:20:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

      New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

      8/29/22 3:20:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

      Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an

      6/1/22 2:30:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

      2/3/21 1:13:21 PM ET
      $SNN
      Industrial Specialties
      Health Care